{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:25:18Z","timestamp":1778599518807,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T00:00:00Z","timestamp":1628208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T00:00:00Z","timestamp":1628208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ital J Pediatr"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cystic fibrosis (CF) is a multisystem disorder, caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. These cause a reduced secretion of chloride, a marked absorption of sodium and, therefore, of water, through the epithelium, resulting in the formation of thickened secretions in organs such as lung or pancreas. These viscous secretions lead to airway obstruction, chronic infection and inflammation resulting in progressive lung damage, bronchiectasis and eventual respiratory failure. Although the average life expectancy has increased over the last 30\u2009years, lung disease is the most common cause of death in people with CF. For these reasons, the improvement of sputum clearance is a major therapeutic aim in CF and early initiation of airway clearance is widely recommended and implemented. Symptomatic mucolytic therapy today is mainly based on inhalation of DNase, hypertonic saline or mannitol, in combination with physiotherapy. Mucolytic agents break down the gel structure of mucus and therefore decrease its elasticity and viscosity, reducing the pulmonary exacerbation frequency and to improve and stabilize lung function. Nevertheless, high quality studies comparing these mucolytic drugs are still few, and the individual experiences of patients and caregivers explain the high variability of their use globally. This review will summarize the current knowledge on hypertonic saline in the treatment of CF lung disease. Furthermore, we report the real-world prescription of inhaled mucolytic agents in CF.<\/jats:p>","DOI":"10.1186\/s13052-021-01117-1","type":"journal-article","created":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T08:03:01Z","timestamp":1628236981000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Hypertonic saline in people with cystic fibrosis: review of comparative studies and clinical practice"],"prefix":"10.1186","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1106-4424","authenticated-orcid":false,"given":"Vito","family":"Terlizzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Masi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Francalanci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Taccetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diletta","family":"Innocenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,6]]},"reference":[{"key":"1117_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","volume":"8","author":"SC Bell","year":"2020","unstructured":"Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, et al. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2020;8:65\u2013124.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"1117_CR2","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jcf.2020.02.015","volume":"19","author":"SG Kapnadak","year":"2020","unstructured":"Kapnadak SG, Dimango E, Hadjiliadis D, Hempstead SE, Tallarico E, Pilewski JM, et al. Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease. J Cyst Fibros. 2020;19(3):344\u201354. https:\/\/doi.org\/10.1016\/j.jcf.2020.02.015.","journal-title":"J Cyst Fibros"},{"key":"1117_CR3","doi-asserted-by":"publisher","first-page":"106073","DOI":"10.1016\/j.rmed.2020.106073","volume":"171","author":"D Salvatore","year":"2020","unstructured":"Salvatore D, Terlizzi V, Francalanci M, Taccetti G, Messore B, Biglia C, et al. Ivacaftor improves lung disease in patients with advanced CF carrying CFTR mutations that confer residual function. Respir Med. 2020;171:106073. https:\/\/doi.org\/10.1016\/j.rmed.2020.106073.","journal-title":"Respir Med"},{"issue":"19","key":"1117_CR4","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton PG, Mall MA, D\u0159ev\u00ednek P, Lands LC, McKone EF, Polineni D, et al. VX17-445-102 study group. Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381(19):1809\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1908639.","journal-title":"N Engl J Med"},{"issue":"9678","key":"1117_CR5","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","volume":"373","author":"BP O'Sullivan","year":"2009","unstructured":"O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009;373(9678):1891\u2013904. https:\/\/doi.org\/10.1016\/S0140-6736(09)60327-5.","journal-title":"Lancet."},{"issue":"1","key":"1117_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s10020-018-0041-6","volume":"24","author":"VM Sofia","year":"2018","unstructured":"Sofia VM, Surace C, Terlizzi V, Da Sacco L, Alghisi F, Angiolillo A, et al. Trans-heterozygosity for mutations enhances the risk of recurrent\/chronic pancreatitis in patients with cystic fibrosis. Mol Med. 2018;24(1):38. https:\/\/doi.org\/10.1186\/s10020-018-0041-6.","journal-title":"Mol Med"},{"issue":"1","key":"1117_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13052-017-0443-z","volume":"44","author":"V Terlizzi","year":"2018","unstructured":"Terlizzi V, Di Lullo AM, Comegna M, Centrone C, Pelo E, Castaldo G, et al. S737F is a new CFTR mutation typical of patients originally from the Tuscany region in Italy. Ital J Pediatr. 2018;44(1):2. https:\/\/doi.org\/10.1186\/s13052-017-0443-z.","journal-title":"Ital J Pediatr"},{"issue":"5","key":"1117_CR8","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.jcf.2014.01.007","volume":"13","author":"V Terlizzi","year":"2014","unstructured":"Terlizzi V, Tosco A, Tomaiuolo R, Sepe A, Amato N, Casale A, et al. Prediction of acute pancreatitis risk based on PIP score in children with cystic fibrosis. J Cyst Fibros. 2014;13(5):579\u201384. https:\/\/doi.org\/10.1016\/j.jcf.2014.01.007.","journal-title":"J Cyst Fibros"},{"issue":"2 Suppl","key":"1117_CR9","doi-asserted-by":"publisher","first-page":"71S","DOI":"10.1378\/chest.107.2_Supplement.71S","volume":"107","author":"MR Knowles","year":"1995","unstructured":"Knowles MR, Olivier KN, Hohneker KW, Robinson J, Bennett WD, Boucher RC. Pharmacologic treatment of abnormal ion transport in the airway epithelium in cystic fibrosis. Chest. 1995;107(2 Suppl):71S\u20136S. https:\/\/doi.org\/10.1378\/chest.107.2_Supplement.71S.","journal-title":"Chest."},{"issue":"1","key":"1117_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000029453","volume":"67","author":"R Dinwiddie","year":"2000","unstructured":"Dinwiddie R. Pathogenesis of lung disease in cystic fibrosis. Respiration. 2000;67(1):3\u20138. https:\/\/doi.org\/10.1159\/000029453.","journal-title":"Respiration."},{"issue":"1","key":"1117_CR11","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1152\/physrev.00010.2005","volume":"86","author":"MC Rose","year":"2006","unstructured":"Rose MC, Voynow JA. Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol Rev. 2006;86(1):245\u201378. https:\/\/doi.org\/10.1152\/physrev.00010.2005.","journal-title":"Physiol Rev"},{"issue":"1","key":"1117_CR12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.prrv.2007.02.009","volume":"8","author":"MO Henke","year":"2007","unstructured":"Henke MO, Ratjen F. Mucolytics in cystic fibrosis. Paediatr Respir Rev. 2007;8(1):24\u20139. https:\/\/doi.org\/10.1016\/j.prrv.2007.02.009.","journal-title":"Paediatr Respir Rev"},{"key":"1117_CR13","first-page":"CD001506","volume":"9","author":"P Wark","year":"2018","unstructured":"Wark P, McDonald VM. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev. 2018;9:CD001506.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"1117_CR14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/ppul.1950200205","volume":"20","author":"B Dasgupta","year":"1995","unstructured":"Dasgupta B, Tomkiewicz RP, Boyd WA, Brown NE, King M. Effects of combined treatment with rhDNase and airflow oscillations on spinnability of cystic fibrosis sputum in vitro. Pediatr Pulmonol. 1995;20(2):78\u201382. https:\/\/doi.org\/10.1002\/ppul.1950200205.","journal-title":"Pediatr Pulmonol"},{"key":"1117_CR15","first-page":"60","volume-title":"Respiratory pharmacology and therapeutics","author":"I Ziment","year":"1978","unstructured":"Ziment I. Respiratory pharmacology and therapeutics. Philadelphia: WB Saunders; 1978. p. 60\u2013104."},{"issue":"10","key":"1117_CR16","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1136\/thx.52.10.900","volume":"52","author":"M Robinson","year":"1997","unstructured":"Robinson M, Hemming AL, Regnis JA, Wong AG, Bailey DL, Bautovich GJ, et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax. 1997;52(10):900\u20133. https:\/\/doi.org\/10.1136\/thx.52.10.900.","journal-title":"Thorax."},{"issue":"2","key":"1117_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/(SICI)1099-0496(199602)21:2<77::AID-PPUL3>3.0.CO;2-M","volume":"21","author":"PA Eng","year":"1996","unstructured":"Eng PA, Morton J, Douglass JA, Riedler J, Wilson J, Robertson CF. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr Pulmonol. 1996;21(2):77\u201383. https:\/\/doi.org\/10.1002\/(SICI)1099-0496(199602)21:2<77::AID-PPUL3>3.0.CO;2-M.","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"1117_CR18","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1136\/thx.2009.125831","volume":"65","author":"R Amin","year":"2010","unstructured":"Amin R, Subbarao P, Jabar A, Balkovec S, Jensen R, Kerrigan S, et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax. 2010;65(5):379\u201383. https:\/\/doi.org\/10.1136\/thx.2009.125831.","journal-title":"Thorax."},{"issue":"12","key":"1117_CR19","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1136\/thx.2004.022590","volume":"59","author":"P Aurora","year":"2004","unstructured":"Aurora P, Gustafsson P, Bush A, Lindblad A, Oliver C, Wallis CE, et al. Multiple breath inert gas washout as a measure of ventilation distribution in children with cystic fibrosis. Thorax. 2004;59(12):1068\u201373. https:\/\/doi.org\/10.1136\/thx.2004.022590.","journal-title":"Thorax."},{"key":"1117_CR20","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jcf.2020.05.010","volume":"19","author":"M Shaw","year":"2020","unstructured":"Shaw M, Khan U, Clancy JP, Donaldson SH, Sagel SD, Rowe SM, et al. PROSPECT Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Changes in LCI in F508del\/F508del patients treated with lumacaftor\/ivacaftor: Results from the prospect study. J Cyst Fibros. 2020;19:931\u20133.","journal-title":"J Cyst Fibros"},{"key":"1117_CR21","doi-asserted-by":"crossref","unstructured":"Terlizzi V, Amato F, Castellani C, Ferrari B, Galietta LJV, Castaldo G, et al. Ex vivo model predicted in vivo efficacy of CFTR modulator therapy in a child with rare genotype. Mol Genet Genomic Med. 2021:e1656.","DOI":"10.1002\/mgg3.1656"},{"issue":"3","key":"1117_CR22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa043900","volume":"354","author":"MR Elkins","year":"2006","unstructured":"Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, et al. National Hypertonic Saline in cystic fibrosis (NHSCF) study group. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006;354(3):229\u201340. https:\/\/doi.org\/10.1056\/NEJMoa043900.","journal-title":"N Engl J Med"},{"issue":"9","key":"1117_CR23","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/S2213-2600(19)30187-0","volume":"7","author":"F Ratjen","year":"2019","unstructured":"Ratjen F, Davis SD, Stanojevic S, Kronmal RA, Hinckley Stukovsky KD, Jorgensen N, et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2019;7(9):802\u20139. https:\/\/doi.org\/10.1016\/S2213-2600(19)30187-0.","journal-title":"Lancet Respir Med"},{"issue":"10","key":"1117_CR24","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1164\/rccm.201807-1203OC","volume":"199","author":"M Stahl","year":"2019","unstructured":"Stahl M, Wielp\u00fctz MO, Ricklefs I, Dopfer C, Barth S, Schlegtendal A, et al. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. Am J Respir Crit Care Med. 2019;199(10):1238\u201348. https:\/\/doi.org\/10.1164\/rccm.201807-1203OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"1117_CR25","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1164\/ajrccm.153.5.8630593","volume":"153","author":"M Robinson","year":"1996","unstructured":"Robinson M, Regnis JA, Bailey DL, King M, Bautovich GJ, Bye PT. Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. Am J Respir Crit Care Med. 1996;153(5):1503\u20139. https:\/\/doi.org\/10.1164\/ajrccm.153.5.8630593.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"1117_CR26","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.jcf.2020.07.009","volume":"19","author":"SH Donaldson","year":"2020","unstructured":"Donaldson SH, Danielle Samulski T, LaFave C, Zeman K, Wu J, Trimble A, et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. J Cyst Fibros. 2020;19(6):942\u20138. https:\/\/doi.org\/10.1016\/j.jcf.2020.07.009.","journal-title":"J Cyst Fibros"},{"issue":"4","key":"1117_CR27","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00408-017-0008-3","volume":"195","author":"ACM Ferreira","year":"2017","unstructured":"Ferreira ACM, Marson FAL, Cohen MA, Bertuzzo CS, Levy CE, Ribeiro AF, et al. Hypertonic saline as a useful tool for sputum induction and pathogen detection in cystic fibrosis. Lung. 2017;195(4):431\u20139. https:\/\/doi.org\/10.1007\/s00408-017-0008-3.","journal-title":"Lung."},{"issue":"21","key":"1117_CR28","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1001\/jama.2012.5214","volume":"307","author":"M Rosenfeld","year":"2012","unstructured":"Rosenfeld M, Ratjen F, Brumback L, Daniel S, Rowbotham R, McNamara S, et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA. 2012;307(21):2269\u201377. https:\/\/doi.org\/10.1001\/jama.2012.5214.","journal-title":"JAMA."},{"issue":"2","key":"1117_CR29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/thoraxjnl-2014-206716","volume":"71","author":"RL Dentice","year":"2016","unstructured":"Dentice RL, Elkins MR, Middleton PG, Bishop JR, Wark PA, Dorahy DJ, et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. Thorax. 2016;71(2):141\u20137. https:\/\/doi.org\/10.1136\/thoraxjnl-2014-206716.","journal-title":"Thorax."},{"issue":"11","key":"1117_CR30","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s12325-010-0076-8","volume":"27","author":"P Buonpensiero","year":"2010","unstructured":"Buonpensiero P, De Gregorio F, Sepe A, Di Pasqua A, Ferri P, Siano M, et al. Hyaluronic acid improves \"pleasantness\" and tolerability of nebulized hypertonic saline in a cohort of patients with cystic fibrosis. Adv Ther. 2010;27(11):870\u20138. https:\/\/doi.org\/10.1007\/s12325-010-0076-8.","journal-title":"Adv Ther"},{"issue":"6","key":"1117_CR31","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1089\/jamp.2015.1256","volume":"29","author":"A Brivio","year":"2016","unstructured":"Brivio A, Conese M, Gambazza S, Biffi A, Tirelli AS, Russo M, et al. Pilot randomized controlled trial evaluating the effect of hypertonic saline with and without hyaluronic acid in reducing inflammation in cystic fibrosis. J Aerosol Med Pulm Drug Deliv. 2016;29(6):482\u20139. https:\/\/doi.org\/10.1089\/jamp.2015.1256.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"1117_CR32","first-page":"CD001127","volume":"3","author":"C Yang","year":"2021","unstructured":"Yang C, Montgomery M. Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev. 2021;3:CD001127.","journal-title":"Cochrane Database Syst Rev"},{"key":"1117_CR33","first-page":"CD001127","volume":"9","author":"C Yang","year":"2018","unstructured":"Yang C, Montgomery M. Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev. 2018;9:CD001127.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"1117_CR34","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/ppul.24306","volume":"54","author":"KW Southern","year":"2019","unstructured":"Southern KW, Clancy JP, Ranganathan S. Aerosolized agents for airway clearance in cystic fibrosis. Pediatr Pulmonol. 2019;54(6):858\u201364. https:\/\/doi.org\/10.1002\/ppul.24306.","journal-title":"Pediatr Pulmonol"},{"issue":"9290","key":"1117_CR35","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/S0140-6736(01)06412-1","volume":"358","author":"R Suri","year":"2001","unstructured":"Suri R, Metcalfe C, Lees B, Grieve R, Flather M, Normand C, et al. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet. 2001;358(9290):1316\u201321. https:\/\/doi.org\/10.1016\/S0140-6736(01)06412-1.","journal-title":"Lancet."},{"issue":"1","key":"1117_CR36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1569-1993(01)00009-1","volume":"1","author":"M Ballmann","year":"2002","unstructured":"Ballmann M, von der Hardt H. Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. J Cyst Fibros. 2002;1(1):35\u20137. https:\/\/doi.org\/10.1016\/S1569-1993(01)00009-1.","journal-title":"J Cyst Fibros"},{"issue":"Suppl 1","key":"1117_CR37","first-page":"S66","volume":"4","author":"FV Adde","year":"2004","unstructured":"Adde FV, Borges KTL, Hatanaka ACF, Nakaie CMA, Cardieri JMA, Oliveira RC, et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients [abstract]. J Cyst Fibros. 2004;4(Suppl 1):S66.","journal-title":"J Cyst Fibros"},{"issue":"2","key":"1117_CR38","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","volume":"17","author":"C Castellani","year":"2018","unstructured":"Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018;17(2):153\u201378. https:\/\/doi.org\/10.1016\/j.jcf.2018.02.006.","journal-title":"J Cyst Fibros"},{"issue":"7","key":"1117_CR39","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","volume":"187","author":"PJ Mogayzel Jr","year":"2013","unstructured":"Mogayzel PJ Jr, Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JB, et al. Marshall B; pulmonary clinical practice guidelines committee. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187(7):680\u20139. https:\/\/doi.org\/10.1164\/rccm.201207-1160OE.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"1117_CR40","doi-asserted-by":"publisher","first-page":"e20151784","DOI":"10.1542\/peds.2015-1784","volume":"137","author":"T Lahiri","year":"2016","unstructured":"Lahiri T, Hempstead SE, Brady C, Cannon CL, Clark K, Condren ME, et al. Clinical practice guidelines from the Cystic Fibrosis Foundation for preschoolers with cystic fibrosis. Pediatrics. 2016;137(4):e20151784. https:\/\/doi.org\/10.1542\/peds.2015-1784.","journal-title":"Pediatrics."},{"issue":"3","key":"1117_CR41","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1034\/j.1399-3003.1999.14c30.x","volume":"14","author":"M Robinson","year":"1999","unstructured":"Robinson M, Daviskas E, Eberl S, Baker J, Chan HK, Anderson SD, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur Respir J. 1999 Sep;14(3):678\u201385. https:\/\/doi.org\/10.1034\/j.1399-3003.1999.14c30.x.","journal-title":"Eur Respir J"},{"key":"1117_CR42","first-page":"CD008816","volume":"2","author":"M Elkins","year":"2020","unstructured":"Elkins M, Dentice R. Timing of hypertonic saline inhalation for cystic fibrosis. Cochrane Database Syst Rev. 2020;2:CD008816.","journal-title":"Cochrane Database Syst Rev"},{"key":"1117_CR43","first-page":"CD007923","volume":"3","author":"R Dentice","year":"2021","unstructured":"Dentice R, Elkins M. Timing of dornase alfa inhalation for cystic fibrosis. Cochrane Database Syst Rev. 2021;3:CD007923.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"1117_CR44","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1159\/000369533","volume":"88","author":"K Hurt","year":"2014","unstructured":"Hurt K, Bilton D. Inhaled interventions in cystic fibrosis: mucoactive and antibiotic therapies. Respiration. 2014;88(6):441\u20138. https:\/\/doi.org\/10.1159\/000369533.","journal-title":"Respiration."}],"container-title":["Italian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-021-01117-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13052-021-01117-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-021-01117-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T08:09:01Z","timestamp":1628237341000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijponline.biomedcentral.com\/articles\/10.1186\/s13052-021-01117-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,6]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1117"],"URL":"https:\/\/doi.org\/10.1186\/s13052-021-01117-1","relation":{},"ISSN":["1824-7288"],"issn-type":[{"value":"1824-7288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,6]]},"assertion":[{"value":"3 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"168"}}